PONTE
VEDRA, Fla., Oct. 9, 2023
/PRNewswire/ -- Cadrenal Therapeutics, Inc., (Nasdaq: CVKD),
a biopharmaceutical company developing tecarfarin, a late-stage
novel oral and reversible anticoagulant (blood thinner) designed to
prevent heart attacks, strokes and deaths due to blood clots in
patients with certain rare medical conditions, announced today that
Quang Pham, CEO, will be
participating in a Company Webcast and Panel Presentation at the
Lytham Partners Fall 2023 Investor Conference on Tuesday, October 17, 2023. Management will also
be conducting one-on-one meetings with investors.
Company Webcast
The Company's webcast presentation
will be available for viewing at 7:00 am ET on Tuesday, October 17, 2023, on the Company's
website at https://www.cadrenal.com/investors/ or
https://wsw.com/webcast/lytham9/cad/1828160. The webcast will also
be archived and available for replay.
Panel Presentation
Additionally, Mr. Pham will be
participating in a panel titled, "Cardiac Kids: Late-Stage
Advancement for Cardiovascular Disorders." This panel, also to be
conducted virtually, will be held on Tuesday, October 17, 2023, at 10:30 am ET. To access the panel, please visit:
https://wsw.com/webcast/lytham9/panel5/2277320.
1x1 Meetings
Management will be participating in
virtual one-on-one meetings throughout the event. To arrange a
meeting with management, please contact Lytham Partners at
1x1@lythampartners.com or register at
https://www.lythampartners.com/fall2023invreg/.
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal
Therapeutics is developing tecarfarin, a late-stage novel oral and
reversible anticoagulant (blood thinner), to prevent heart attacks,
strokes, and deaths due to blood clots in patients with certain
rare medical conditions. Tecarfarin has orphan drug and Fast Track
designations for the prevention of systemic thromboembolism (blood
clots) of cardiac origin in patients with ESKD and AFib. Tecarfarin
is specifically designed to leverage a different metabolism pathway
than the oldest and most commonly prescribed Vitamin K Antagonist
(warfarin) used in the prevention of thrombosis. Tecarfarin has
been evaluated in eleven (11) human clinical trials and more than
1,000 individuals. In Phase 1, Phase 2, and Phase 2/3 clinical
trials, tecarfarin has generally been well-tolerated in both
healthy adult subjects and patients with chronic kidney disease.
For more information, please visit:
www.cadrenal.com.
For more information, please contact:
Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com
Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-to-participate-in-the-lytham-partners-fall-2023-investor-conference-301951137.html
SOURCE Cadrenal Therapeutics, Inc.